Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains

Simply Wall St.04-22

AdvertisementCelldex Therapeutics stock snapshot Celldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629028854?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-22 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629028854","market":"us","top_or_hot":-1,"title":"Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementCelldex Therapeutics stock snapshot Celldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementCelldex Therapeutics stock snapshot Celldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDX","symbol_name":"塞德斯医疗","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r","article_id":"2629028854","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629028854","pubTimestamp":1776863611,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Celldex Therapeutics stock snapshot\nCelldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the past month and 30.9% over the past 3 months.\nSee our latest analysis for Celldex Therapeutics.\nShort term momentum has been firm, with a 30 day share price return of 10.8% and a 90 day gain of 30.9%, while the 1 year total shareholder return of 76.6% reflects a strong recent run compared with its longer term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDX":"塞德斯医疗","BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在近期股价强劲上涨后评估Celldex Therapeutics(CLDX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":1.5,"DCF":1},"content_text":"AdvertisementCelldex Therapeutics stock snapshot Celldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the past month and 30.9% over the past 3 months. See our latest analysis for Celldex Therapeutics. Short term momentum has been firm, with a 30 day share price return of 10.8% and a 90 day gain of 30.9%, while the 1 year total shareholder return of 76.6% reflects a strong recent run compared with its longer term record. If Celldex’s move has you looking wider in healthcare, this is a good moment to see what else is setting up in 34 healthcare AI stocks With Celldex posting a 76.6% 1 year total return, annual revenue of just $1.545 million and an intrinsic value estimate that implies a 57.1% discount, you have to ask: is this a genuine opportunity or is the market already pricing in future growth? Preferred Price to Book of 5.1x: Is it justified? On a P/B of 5.1x, Celldex Therapeutics looks cheaper than its immediate peer group on this metric, yet more expensive than the broader US biotech industry. P/B compares a company’s market value to the book value of its net assets, which can be a useful cross check for asset backed or early stage businesses where earnings are still negative. For a development stage biopharma like Celldex, it often reflects what the market is willing to pay today for the current cash, R&D assets and pipeline potential rather than current profits. Here, Celldex’s 5.1x P/B sits below a peer average of 7.7x. This suggests investors are paying less per dollar of book value than for some similar names. At the same time, that 5.1x multiple is above the broader US biotech industry average of 2.5x. This indicates the market is still assigning a premium to Celldex’s balance sheet and pipeline relative to many smaller biotech names, even as the company remains unprofitable. See what the numbers say about this price — find out in our valuation breakdown. Result: Price to book ratio of 5.1x (ABOUT RIGHT) However, there are clear risks to keep in mind, including Celldex’s US$258.757 million loss and the execution challenge involved in advancing a largely early stage antibody pipeline. Find out about the key risks to this Celldex Therapeutics narrative. Another View: What the DCF Model Suggests The P/B comparison paints Celldex as roughly in line with peers, yet our DCF model points in a different direction. With an estimated fair value of $79.92 per share compared with a $34.25 price, the SWS DCF model suggests the stock could be materially undervalued. Which signal do you trust more? Look into how the SWS DCF model arrives at its fair value. CLDX Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps The mix of strong recent returns and early stage risks can feel conflicting, so it makes sense to review the details yourself and decide where you stand, starting with the 2 key rewards and 3 important warning signs Looking for more investment ideas? If Celldex has caught your eye, do not stop here. Use the screener to uncover other opportunities that could fit your goals before the crowd notices.  Target long term compounding potential by scanning for companies trading below estimated value using the 58 high quality undervalued stocks. Prioritise staying power by focusing on businesses with stronger balance sheets through the solid balance sheet and fundamentals stocks screener (41 results). Hunt for overlooked opportunities by filtering a screener containing 23 high quality undiscovered gems that may not yet be on most investors’ radars.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629028854","isCrawlerRequest":true}